Last updated: 11/07/2018 19:16:22
A Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparison of the Salmeterol/Fluticasone Propionate Combination Product (50/100mcg strength) BD Via One DISKUS/ACCUHALER Inhaler with Salmeterol 50mcg BD Via One DISKUS/ACCUHALER and Fluticasone Propionate 100mcg BD Via a Sec ...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparison of the Salmeterol/Fluticasone Propionate Combination Product (50/100mcg strength) BD Via One DISKUS/ACCUHALER Inhaler with Salmeterol 50mcg BD Via One DISKUS/ACCUHALER and Fluticasone Propionate 100mcg BD Via a Sec ...
Trial description: A Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparison of the Salmeterol/Fluticasone Propionate Combination Product (50/100mcg strength) BD Via One DISKUS/ACCUHALER Inhaler with Salmeterol 50mcg BD Via One DISKUS/ACCUHALER and Fluticasone Propionate 100mcg BD Via a Sec ...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: combined salmeterol xinafoate and fluticasone propionate (50/100 micro gram strength) bd via one diskus (accuhaler) inhaler compared with salmeterol xinafoate 50 micro gram and fluticasone propionate 100 micro gram bd via two separate diskus inhalers. van den Berg, N J, Ossip, M, Hederos, C A, Anttila, H, and Davies, P 8th Annual Congress of the European Respiratory Society 9/19/1998 Geneva Switzerland
Van den Berg NJ, Ossip MS, Hederos CA, Antilla H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 ?g) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30 (2): 97-105.
Medical condition
Airway Obstruction
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
November 1996 to September 1997
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-10-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website